Equity Profile

CELC

Celcuity Inc.

Health CareBiotechnology$4.3B

Aug13Thu

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Celcuity Inc. is a biotechnology company focused on developing innovative cancer therapies....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and investor sentiment.

$-1.18

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products.

$7M

Wall Street expectations, options signals, track record, and call prep available with Pro.

CELC Q2-2026 Earnings Preview

Context

Company Snapshot

Celcuity Inc. is a biotechnology company focused on developing innovative cancer therapies. With a market cap of $4 billion, it operates in the health care sector, which is increasingly important as advancements in personalized medicine continue to shape treatment options for patients.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+10.76%

Avg Stock Reaction

+1.94%

Last Quarter Recap

In Q1-2026, Celcuity reported an EPS of $-0.86, which was better than the expected $-1.07, resulting in an 8.23% stock increase the following day. However, revenue details were not disclosed.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Celcuity to report a loss of $-1.18 per share with revenue around $7 million. Given the company's history of beating EPS estimates, there is cautious optimism.

Bull Case

If Celcuity can exceed the EPS estimate and show strong revenue growth, it could signal robust demand for its cancer therapies, leading to a positive stock reaction.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could raise concerns about its product pipeline and market position, negatively impacting the stock.

Key Metrics to Watch

EPS

$-1.18

Earnings per share is a key indicator of profitability and investor sentiment.

Revenue

$7M

Revenue figures provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Celcuity's EPS exceed the consensus estimate of $-1.18?

A better-than-expected EPS could boost investor confidence and lead to a positive stock reaction.

What revenue figure will Celcuity report, and how does it compare to the $7 million consensus?

Revenue performance is critical for understanding market demand and the company's growth trajectory.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate the potential for Celcuity to exceed its EPS estimates based on its recent performance trends.

Supporting Evidence

Celcuity has a 75% EPS beat rate over the last eight quarters, indicating a strong likelihood of exceeding expectations.

The options market is pricing in a larger move than historical averages, suggesting heightened investor interest and potential for positive surprises.

Key Risk

If Celcuity's revenue comes in significantly above $7 million, it could shift market sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Celcuity can sustain its recent performance and meet or exceed expectations in a competitive biotechnology landscape.

Bull Confirmed If

An EPS of better than $-1.18 and revenue exceeding $7 million would confirm the bull case.

Bear Confirmed If

An EPS worse than $-1.18 and revenue significantly below $7 million would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±12.47%

Historical Avg

±4.1%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±12.5% while CELC has averaged ±4.1% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

73.5%

Calls (79K)P/C Ratio: 0.54Puts (54K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 14 of 29 (48%)

This setup has occurred 30 times across Health Care in the last 2 years. 14 of 29 faded and 15 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Celcuity beats expectations, history suggests a stock increase of around 3.4%, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may react cautiously, reflecting uncertainty in future growth.

Miss

A miss could lead to a decline of about 2.4%, as seen in past quarters when expectations were not met.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the progress of Celcuity's cancer therapies and their market readiness.
2Insights into the competitive landscape and how Celcuity plans to differentiate its products.
3Management's commentary on operational efficiency and cost management strategies.
4Details on any partnerships or collaborations that could enhance growth prospects.
5Guidance on future revenue expectations and product pipeline developments.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

ePlus inc.

Company Snapshot

Celcuity Inc. is a biotechnology company focused on developing innovative cancer therapies....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and investor sentiment.

$-1.18

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products.

$7M

Wall Street expectations, options signals, track record, and call prep available with Pro.

CELC Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+10.76%

Avg Stock Reaction

+1.94%

Last Quarter Recap

In Q1-2026, Celcuity reported an EPS of $-0.86, which was better than the expected $-1.07, resulting in an 8.23% stock increase the following day. However, revenue details were not disclosed.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Celcuity to report a loss of $-1.18 per share with revenue around $7 million. Given the company's history of beating EPS estimates, there is cautious optimism.

Bull Case

If Celcuity can exceed the EPS estimate and show strong revenue growth, it could signal robust demand for its cancer therapies, leading to a positive stock reaction.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could raise concerns about its product pipeline and market position, negatively impacting the stock.

Key Metrics to Watch

EPS

$-1.18

Earnings per share is a key indicator of profitability and investor sentiment.

Revenue

$7M

Revenue figures provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Celcuity's EPS exceed the consensus estimate of $-1.18?

A better-than-expected EPS could boost investor confidence and lead to a positive stock reaction.

What revenue figure will Celcuity report, and how does it compare to the $7 million consensus?

Revenue performance is critical for understanding market demand and the company's growth trajectory.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate the potential for Celcuity to exceed its EPS estimates based on its recent performance trends.

Supporting Evidence

Celcuity has a 75% EPS beat rate over the last eight quarters, indicating a strong likelihood of exceeding expectations.

The options market is pricing in a larger move than historical averages, suggesting heightened investor interest and potential for positive surprises.

Key Risk

If Celcuity's revenue comes in significantly above $7 million, it could shift market sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Celcuity can sustain its recent performance and meet or exceed expectations in a competitive biotechnology landscape.

Bull Confirmed If

An EPS of better than $-1.18 and revenue exceeding $7 million would confirm the bull case.

Bear Confirmed If

An EPS worse than $-1.18 and revenue significantly below $7 million would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±12.47%

Historical Avg

±4.1%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±12.5% while CELC has averaged ±4.1% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

73.5%

Calls (79K)P/C Ratio: 0.54Puts (54K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 14 of 29 (48%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Celcuity beats expectations, history suggests a stock increase of around 3.4%, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may react cautiously, reflecting uncertainty in future growth.

Miss

A miss could lead to a decline of about 2.4%, as seen in past quarters when expectations were not met.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the progress of Celcuity's cancer therapies and their market readiness.
2Insights into the competitive landscape and how Celcuity plans to differentiate its products.
3Management's commentary on operational efficiency and cost management strategies.
4Details on any partnerships or collaborations that could enhance growth prospects.
5Guidance on future revenue expectations and product pipeline developments.